Vasoplegic Syndrome
Conditions
Brief summary
After cardiac surgery, vasoplegic syndrome is a hemodynamic state characterized by profound hypotension associated with a decrease in systemic vascular resistance. The care of this disease is based on the intravenous administration of a vasopressor, usually norepinephrine. During the recovery phase, weaning of norepinephrine, is an important step in which any lack of preload (blood volume) initial or secondary can be, and increase tissue malperfusion.
Interventions
DRUGNorepinephrine
Administration and weaning of norepinephrine is based on dynamic arterial elastance
Sponsors
Centre Hospitalier Universitaire, Amiens
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Major patient ≥ 18 years * Patient operated a cardiac surgery for myocardial revascularization (CABG surgery) or surgical correction of valvular or combined surgery (CABG and valve disease) or surgery the ascending aorta and cardiac surgery with vasoplegic syndrome treated by norepinephrine * Signed consent * Affiliation to social assurance
Exclusion criteria
* Permanent atrial fibrillation * Treatment with dobutamine and/or epinephrine * Pregnant woman * Patient under guardianship or private public law * Internal pacemaker * Hypothermia * Patient refusal
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The duration of treatment with norepinephrine. | Day 28 | Mean duration time of norepinephrine administration calculated in hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| ICU duration of stay in day | Day 28 | — |
| Total urine output in ml during the study period | Day 28 | — |
| Total of crystalloid an colloid infused during the study period (ml) | Day 28 | — |
| The total dose of norepinephrine infused during the study period | Day 28 | — |
| Incidence of postoperative atrial arrhythmias (Ac/Fa, Ventricular tachycardia, Ventricular flutter, Ventricular fibrillation) during the study period | Day 28 | — |
| SOFA score | Day 28 | SOFA score measured at the end of norepinephrine administration |
| the rate of arterial lactate at the end of norepinephrine administration | Day 28 | — |
Countries
France
Outcome results
None listed